

FDA Approved CDx	Tumor Type	Scoring Method	FDA Approved Therapy
PD-L1 IHC 22C3	Non-Small Cell Lung Cancer (NSCLC)	Tumor Proportion Score (TPS)	Keytruda® (pembrolizumab)
	Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Cervical Cancer	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Urothelial Carcinoma (URC)	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
PD-L1 IHC SP142	Urothelial Carcinoma (URC)	Tumor-Infiltrating Immune Cell (IC) Score (%)	Tecentriq® (atezolizumab)